6533b862fe1ef96bd12c6d4e
RESEARCH PRODUCT
Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study
Patrizia SantoroCarlo LisottoFilippo BrighinaBrigida FierroBiagio PanasciaFerrariMarco BartoliniGiorgio ZanchinLa PiniGrazia SancesPaolo MartellettiMaria Adele GiamberardinoD. MoscatoStefano OmboniLidia Savisubject
medicine.medical_specialtyeducation.field_of_studyTraditional medicinebusiness.industrymedia_common.quotation_subjectPopulationPain reliefClinical NeurologySubgroup analysisGeneral Medicinemedicine.diseaseAnesthesiology and Pain MedicineMigraineInternal medicineAlmotriptanFemale patientPoster PresentationmedicineNeurology (clinical)FrovatriptaneducationbusinessMenstrual cyclemedicine.drugmedia_commondescription
Results 67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2and 4-hrs was 36% and 53% for frovatriptan and 41% and 50% for almotriptan (p=NS between treatments). Rate of pain free at 2and 4-hrs was 19% and 47% with frovatriptan and 29% and 54% for almotriptan (p=NS). At 24-hrs, 62% of frovatriptanand 67% of almotriptan-treated patients had pain relief, while 60% vs. 67% were pain free (p=NS). Recurrence at 24-hrs was significantly (p<0.05) lower with frovatriptan (8% vs. 21% almotriptan). This was the case also at 48-hrs (9% vs. 24%, p<0.05).
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2013-02-28 | The Journal of Headache and Pain |